Login / Signup

Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.

Sai ChenHefei RenXiaomin ZhangLiu ChangZhenhua WangHongkun WuJiafeng ZhangJigang RenLin Zhou
Published in: Journal of clinical laboratory analysis (2022)
Dysregulated m6A and its related factors in pancreatic cancer cells and patients indicate their potential values as novel biomarkers in pancreatic cancer diagnosis and targeted therapy.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • stem cells
  • patient reported outcomes
  • risk assessment
  • bone marrow